1. Home
  2. AGEN vs DOMH Comparison

AGEN vs DOMH Comparison

Compare AGEN & DOMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGEN
  • DOMH
  • Stock Information
  • Founded
  • AGEN 1994
  • DOMH 1967
  • Country
  • AGEN United States
  • DOMH United States
  • Employees
  • AGEN N/A
  • DOMH N/A
  • Industry
  • AGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • DOMH Biotechnology: Pharmaceutical Preparations
  • Sector
  • AGEN Health Care
  • DOMH Health Care
  • Exchange
  • AGEN Nasdaq
  • DOMH Nasdaq
  • Market Cap
  • AGEN 87.7M
  • DOMH 74.7M
  • IPO Year
  • AGEN 2000
  • DOMH N/A
  • Fundamental
  • Price
  • AGEN $5.29
  • DOMH $5.43
  • Analyst Decision
  • AGEN Strong Buy
  • DOMH
  • Analyst Count
  • AGEN 3
  • DOMH 0
  • Target Price
  • AGEN $16.33
  • DOMH N/A
  • AVG Volume (30 Days)
  • AGEN 1.2M
  • DOMH 249.3K
  • Earning Date
  • AGEN 08-11-2025
  • DOMH 08-11-2025
  • Dividend Yield
  • AGEN N/A
  • DOMH 5.88%
  • EPS Growth
  • AGEN N/A
  • DOMH N/A
  • EPS
  • AGEN N/A
  • DOMH N/A
  • Revenue
  • AGEN $99,524,000.00
  • DOMH $24,891,000.00
  • Revenue This Year
  • AGEN $25.31
  • DOMH N/A
  • Revenue Next Year
  • AGEN N/A
  • DOMH N/A
  • P/E Ratio
  • AGEN N/A
  • DOMH N/A
  • Revenue Growth
  • AGEN N/A
  • DOMH 630.80
  • 52 Week Low
  • AGEN $1.38
  • DOMH $0.83
  • 52 Week High
  • AGEN $7.34
  • DOMH $13.58
  • Technical
  • Relative Strength Index (RSI)
  • AGEN 44.92
  • DOMH 55.73
  • Support Level
  • AGEN $5.34
  • DOMH $4.31
  • Resistance Level
  • AGEN $6.58
  • DOMH $5.30
  • Average True Range (ATR)
  • AGEN 0.44
  • DOMH 0.37
  • MACD
  • AGEN -0.16
  • DOMH -0.00
  • Stochastic Oscillator
  • AGEN 10.69
  • DOMH 72.73

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

About DOMH Dominari Holdings Inc.

Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.

Share on Social Networks: